Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

IntroductionThe role of prednisone in the prevention of androgen receptor antagonist-related rash and treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is unclear. This pilot trial (ChiCTR2200060388) aimed to investigate the feasibility of apalutamide combined with androgen deprivat...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Dingyuan Yang, Wenqiang Chen, Fei Lai, Mingxing Qiu, Jun Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Subjects:	apalutamide metastatic hormone-sensitive prostate cancer prednisone randomized controlled trial rash
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1110807/full